Metastasis is the major reason for breast cancer-related deaths. Although there is a host of indirect evidence for a role of protein kinase C (PKC) a in primary breast cancer growth, its role in the molecular pathways leading to metastasis has not been studied comprehensively. By treating mice with aV5-3, a novel peptide inhibitor selective for PKCa, we were able to determine how PKCa regulates metastasis of mammary cancer cells using a syngeneic and orthotopic model. The primary tumor growth was not affected by aV5-3 treatment. However, the mortality rate was reduced and metastasis in the lung decreased by more than 90% in the aV5-3-treated mice relative to the control-treated mice. aV5-3 treatment reduced intravasation by reducing matrix metalloproteinase-9 activities. aV5-3 treatment also reduced lung seeding of tumor cells and decreased cell migration, effects that were accompanied by a reduction in nuclear factor kappa B activity and cell surface levels of the CXCL12 receptor, CXCR4. aV5-3 treatment caused no apparent toxicity in non-tumor-bearing naı¨ve mice. Rather, inhibiting PKCa protected against liver damage and increased the number of immune cells in tumorbearing mice. Importantly, aV5-3 showed superior efficacy relative to anti-CXCR4 antibody in reducing metastasis in vivo. Together, these data show that pharmacological inhibition of PKCa effectively reduces mammary cancer metastasis by targeting intravasation and lung seeding steps in the metastatic process and suggest that PKCa-specific inhibitors, such as aV5-3, can be used to study the mechanistic roles of PKCa specifically and may provide a safe and effective treatment for the prevention of lung metastasis of breast cancer patients.
Introduction
Breast cancer is the leading cause of cancer-related deaths among women in the developed world and metastasis is the most common cause for the morbidity and mortality (Christofori, 2007; Podsypanina et al., 2008) . Formation of metastasis is a multistep process associated with breakdown of the extracellular matrix surrounding the primary tumor, intravasation of tumor cells into the surrounding blood vessels, as well as migration, adhesion, survival and proliferation of these cancer cells at secondary sites (Muller et al., 2001; Christofori, 2007) . The identification of new treatments that target critical events in the formation of metastasis without causing systemic toxicity is likely to benefit patients with advanced breast cancer.
Protein kinase C (PKC), a family of highly homologous serine/threonine protein kinases, has been implicated in a variety of processes important to tumor progression, including cancer cell proliferation, migration, invasion and survival (Griner and Kazanietz, 2007) . Among the PKC isozymes, upregulation and activation of PKCa has been suggested to be important in breast cancer (Borner et al., 1987; O'Brian et al., 1989; Ways et al., 1995; Tonetti et al., 2003; Assender et al., 2007; Frankel et al., 2007) . Specifically, (i) PKCa expression is higher in human breast cancer tissues compared with normal tissues from the same patients (O'Brian et al., 1989) ; (ii) there is a negative correlation between PKCa levels and estrogen receptor-a levels (a marker of positive prognosis) in human breast cancer cell lines (Borner et al., 1987; Assender et al., 2007) ; (iii) PKCa activity is significantly higher in tamoxifenresistant human breast cancer cell lines as compared with tamoxifen-responsive parental cells (Frankel et al., 2007) ; (iv) accordingly, patients with PKCa-positive breast tumors were found to be resistant to tamoxifen treatment earlier than those with PKCa-negative tumors (Tonetti et al., 2003) . Furthermore, PKCa overexpression reduced mRNA levels of estrogen receptors and increased the invasiveness of human MCF-7 breast cancer cells, as measured in vitro and in a xenograft model (Ways et al., 1995) . However, a comprehensive syngeneic in vivo study investigating the signaling events involving PKCa in the molecular pathways leading to metastasis has not been carried out owing to the lack of isozyme-specific tools to selectively inhibit the activity of this isozyme without toxicity. Therefore, we set out to define the steps wherein PKCa activity is critical during metastasis and to investigate the mechanisms by which PKCa regulates these steps, using in vivo imaging in a syngeneic orthotopic tumor model in immunocompetent mice.
We used a novel isozyme-specific inhibitor peptide of PKCa, designed from its V5 region, based on a rational approach that we described before (Mochly-Rosen and Gordon, 1998; Stebbins and Mochly-Rosen, 2001 ). Briefly, the PKCa inhibitor, aV5-3, is derived from a unique sequence in the highly variable region, V5, of this enzyme. We already found that PKC-derived peptides corresponding to the same position in the V5 region of PKCbI and bII serve as selective inhibitors for the corresponding isozyme (Stebbins and Mochly-Rosen, 2001) .
Until recently, the details of the metastatic processes in vivo remained vague owing to the lack of imaging techniques with sufficient sensitivity and resolution to monitor cells engaged in the metastatic processes (Sahai, 2007) . Here, we expressed firefly luciferase in mouse and human breast cancer cells and used whole body/tissue bioluminescence imaging techniques to detect the appearance of lung metastases and to follow the progression of the disease over time, in the same animal (Thorne and Contag, 2005) . Bioluminescence imaging allows non-invasive in vivo imaging of metastatic sites with a high level of sensitivity (Sahai, 2007) .
We found that PKCa inhibition with aV5-3 in vivo almost completely abrogates metastasis of breast cancer to the lungs and other organs in mice, which correlated with increased survival of these tumor-bearing animals. The PKCa antagonistic peptide inhibits intravasation, cell migration and lung seeding of tumor cells that lead to lung metastasis. We further demonstrated that treatment with aV5-3 not only shows no discernable toxicity in naı¨ve, non-tumor bearing mice, but also shows potential benefits by protecting against cancerinduced liver damage and normalization of blood cell counts in tumor-bearing animals. The pharmacological efficacy of aV5-3 was compared with that of an antimetastatic drug that is currently being developed for human clinical experiments. The relevance of our findings to human breast cancer is discussed.
Results
PKCa is more active in metastatic mammary cancer cells relative to non-metastatic cancer cells 4T1 and JC are both mouse mammary cancer cell lines, syngeneic for BALB/c mice. Following orthotopic implantation of 4T1 or JC cells into BALB/c mice, the size of the respective primary tumors increased at similar rates ( Figure 1a , upper panel). However, whereas 4T1 cells were highly metastatic (primarily in the lungs), as monitored by in vivo bioluminescence imaging, JC cells did not metastasize, even at late time points (Figure 1a , lower panel and right panel, two-tailed unpaired t test, Po0.05). Among the dozen PKC isozymes, PKCa, bII and e were previously reported to regulate the metastatic behavior of breast cancer cells (Pan et al., 2005; Sledge and Gokmen-Polar, 2006; Martiny-Baron and Fabbro, 2007 ). We therefore compared the level of their activation in the highly metastatic 4T1 cells with that in the non-metastatic JC cells by measuring their subcellular distribution; the presence of PKC in the particulate fraction is a measure of activation of the kinase (Kraft et al., 1982) . Of the PKC isozymes studied, only the levels of PKCa in the particulate fraction were significantly higher in 4T1 cells as compared with JC cells (Figure 1b , left, two-tailed unpaired t test, Po0.05). In contrast, the levels of PKCbII in the particulate fraction were six times lower in the metastatic 4T1 cells as compared with non-metastatic JC cells (Figure 1b, middle) and the percent activation of PKCe was not significantly different between these two cell lines (Figure 1b, right) . Subcellular distribution of PKCa, bII and e in 4T1 cells recovered from orthotopic tumors isolated from mice 4 weeks after implantation showed that PKCa is also the most active form in the 4T1 tumors, in vivo ( Figure 1c , n ¼ 4 each, *Po0.05 vs PKCa). As 4T1 cells are highly metastatic, we set out to determine whether the increased level of PKCa activation in 4T1 cells has a role in regulating mammary cancer metastasis.
Inhibition of PKCa reduces tumor metastasis in vivo
To determine whether PKCa has a role in the metastasis of 4T1-luc cells in vivo, we treated mice with control, carrier peptide (TAT [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] ; 24 mg/kg/day) or with equimolar concentration of aV5-3-TAT 47-57 (aV5-3; a PKCa inhibitory peptide that is conjugated to cell-permeable TAT 47-57 for intracellular delivery; 35 mg/kg/day) for 4 weeks, starting a week after orthotopic tumor cell implantation in the mammary fat pad (Figure 2a ). This time point was chosen because we found 4T1-luc cells in the lungs 7-10 days after cancer cell implantation ( Figure 1a) . Treatment for 4 weeks with aV5-3 almost completely prevented metastasis to the lungs and caused a significant reduction in metastasis to the rib cages ( Figure 2b , top and bottom), two of the major sites of metastasis (Smith et al., 2004) . These data indicate that PKCa plays a major role in metastasis in this model.
We confirmed the isozyme-specific inhibition following aV5-3 treatment by determining subcellular distribution of PKC isozymes in primary tumor lysates from the treated mice. Whereas PKCbII activation was unaffected, the active level of PKCa was B65% lower in the tumor of the aV5-3-treated mice relative to that of the control-treated mice (Figures 2c and d) . The same loading controls were used for Figures 2c and d. (Note also that aV5-3 treatment did not affect the total cellular levels of these isozymes; see the sum of cytosolic and particulate fractions in the blots of Figures 2c and d) . Together, these results suggest that metastasis of 4T1-luc tumors requires PKCa activity and that aV5-3 specifically inhibits this activity.
Inhibition of PKCa blocks metastasis at the intravasation stage Metastasis is a multistep process, and it is likely that different cellular processes are important for these different stages. We therefore set out to identify the step(s) regulated by PKCa. We broadly divided the metastasis process into two phases: escape of tumor cells from the primary tumor and seeding of secondary organs. We first examined the effects of PKCa inhibition on tumor intravasation, using an in vitro assay. This assay measures the movement of tumor cells through an endothelial cell layer and thus mimics the movement of tumor cells out of the primary tumor and into circulation, that is, intravasation. We treated 4T1-luc cells with TAT or aV5-3 and measured passage through a mouse endothelial cell layer and into a Matrigel plug ( Figure 3a ). aV5-3 treatment reduced the ability of 4T1 cells to cross the endothelial cell barrier by more than 75%, relative to control treatment ( Figure 3a ). We also determined the effects of aV5-3 on human breast cancer cells, MDA-MB-231-luc and their ability to pass through a human umbilical vein endothelial cell monolayer ( Figure 3b ). This was both to verify that the data obtained with the mouse cell line were relevant to the human disease, and to ensure that the effects were not influenced by the use of a transformed endothelial cell line. We found that aV5-3 treatment reduced the intravasation of the highly metastatic MDA-MB-231 cells, by B55% as compared with TAT treatment (Figure 3b ). On the basis of these in vitro assays, it appears that PKCa activation is required for the movement of tumor cells out of the primary tumor and into the vessels.
Next, we examined the molecular mechanisms behind this protection against intravasation conferred by PKCa inhibition. MMPs are known to be major regulators of intravasation through their degradation of matrix proteins (Zucker et al., 2000; Noel et al., 2008) and proteinases MMP-2 and -9 and the serine protease, urokinase-type plasminogen activator, has been reported to regulate breast cancer metastasis (Tester et al., 2000; Chakraborti et al., 2003; Ke et al., 2006; Mi et al., 2006) . We therefore determined MMP-2, -9 and urokinase type plasminogen activator activities in both the primary tumors and metastasized tumors in the lungs of TAT or aV5-3-treated animals; urokinase type plasminogen activator was not significantly affected in either the primary or the metastatic tumor (data not shown), but treatment with aV5-3 reduced the activities of MMP-9 in the primary tumors by about 40% (Figure 3c ). These data indicate that aV5-3 inhibition of MMP activities may result in decreased intravasation of mammary tumor cells.
We then treated 4T1-luc cells with an MMP-9 inhibitor, SB-3CT, and compared their MMP-9 activities with cells transfected with small interfering (si)RNA of PKCa. We found that SB-3CT decreased MMP-9 activities by 60±6% ( Figure 3d , n ¼ 4) and cells transfected with siRNA of PKCa had 50±3% lower activity of MMP-9 (Figure 3d , n ¼ 4). Taken together, these data suggest that PKCa regulates intravasation of cancer cells from the primary tumors mediated by MMP-9 activity.
Inhibition of PKCa protects against seeding of 4T1 cancer cells to the lungs We next determined whether PKCa regulates seeding of cells in the secondary organs. We used a 'lung seeding' assay in vivo (Smith et al., 2004) , wherein intravenous injection of tumor cells results in seeding of the cells in the lung. This assay is designed to mimic migration, adhesion to target organ vasculature and survival, all the events that occur after intravasation of tumor cells into circulation.
TAT and aV5-3 peptides were administered continuously using an osmotic pump that was implanted in the mouse flank 2 days before tumor cell injection. The 4T1 tumor cells labeled with luciferase were injected through the tail vein and the animals were imaged 5 days later. Treatment with aV5-3 significantly reduced the presence of cancer cells in the lungs as determined on day 5 (Figure 4a ). The 45% reduction in tumor burden in the lung on day 5 after cell injection was encouraging, as this may represent reductions in tissue adhesion and/or invasion to the metastatic site and/or survival of tumor cells in that site, all leading to reduced tumor burden in the lung.
To determine whether the reduction in tumor burden following lung seeding was due to reduced numbers of tumor nodules, or a reduced tumor nodule size, we carried out histological examination of the lung tissues obtained from animals treated in the same way and analyzed the lung tissue 2 weeks after the treatments (Figure 4b ). Treatment with aV5-3 greatly reduced the number of lung nodules as compared with the PKCa antagonist peptide inhibits mammary tumor metastasis J Kim et al TAT-treated group (arrows; nodules, Po0.05), but the size of the individual nodules did not appear to be significantly affected (Supplementary Figure 3) . These data are consistent with lack of an effect of the PKCa inhibitor on the rate of tumor cell proliferation (Supplementary Figure 7A-D) and again imply a selective inhibitory effect of this treatment on metastasis.
We further determined survival of the mice in the two treatment groups following lung seeding and found that mice injected intravenously with the aggressive 4T1 tumor cells and treated with aV5-3 survived significantly longer as compared with the TAT-treated mice (Figure 4c , P ¼ 0.027); 70% of the aV5-3-treated animals survived for 30 days, whereas only 10% of the TAT-treated animals were alive at that time. These data suggest that inhibition of PKCa also increases survival of the mammary tumor-bearing mice by decreasing lung seeding of the tumor cells.
aV5-3 reduces cell migration and cell surface levels of CXCR4, and produces a greater reduction in metastasis than anti-CXCR4 antibody in vivo Using an in vitro assay with Becton Dickinson, chambers (Becton Dickinson, Bedford, MA, USA), we found that aV5-3 treatment significantly inhibited cell migration, as well as invasion, as compared with TAT controls (Figure 5a ). In conjunction with its cognate ligand, CXCL12, CXCR4 regulates normal lymphocyte trafficking as well as metastatic migration of mammary tumor cells, other cancer cells and lymphocytes (Muller et al., 2001; Taichman et al., 2002; Smith et al., 2004) . We therefore determined the levels of the chemokine receptor, CXCR4. After treatment of mice bearing 4T1 tumors with aV5-3 for 4 weeks, the cell surface CXCR4 levels in the tumors were 80% lower as compared with those in the TAT-control group (Figure 5b ). Of note, CXCR4 was not detected on the surface of 4T1 cells Mouse tumor endothelial cells (2H-11, ATCC) were grown on top of a Matrigel plug in tissue culture inserts in 24-well plates until they formed a confluent monolayer. Breast cancer cells (1 000 000 cells/well) expressing luciferase were then added above the endothelial cell layer and peptides were added as indicated, to a final concentration of 10 mm. Peptides were re-applied every 2 h for 10 h and the cells were then incubated for a further 14 h (a total of 24 h). At the end of this time, cell media was aspirated and a cotton swab was used to remove the endothelial cell layer. The Matrigel plug was then imaged (IVIS50; Xenogen, part of Caliper Life Sciences) after addition of luciferin. Bioluminescence produced was used to quantify the number of labeled tumor cells that had crossed the endothelial cell layer and entered the Matrigel plug. (b) The experiment was repeated looking at the invasion of human MDA-MB-231-luc breast cancer cells across primary human endothelial human umbilical vein endothelial cells (TAT treatment in clear bars and aV5-3 treatment in blue bars, n ¼ 4). (c) Activities of MMP-9 in primary tumors were measured by in-gel zymography in homogenates of tumors isolated from mice treated as described in Figure 2 . Molecular weights of pro-and active forms of MMP-9 are shown. (d) Activities of secreted MMP-9 were measured from cultures of 4T1-luc cells treated with vehicle (dimethyl sulfoxide (DMSO), control) and SB-3CT (an MMP-9 inhibitor, 10 mm in DMSO) (n ¼ 3 for each). Cells were treated for 24 h and media was collected and analyzed for MMP-9 activities. Also, MMP-9 activities were measured in the medium from cells treated with control (ctrl) siRNA and siRNA of PKCa for 48 h and cultured for 2 more days. A full colour version of this figure is available at the Oncogene journal online.
grown in culture (unpublished data and Smith et al., 2004) , highlighting the importance of using in vivo models to accurately determine the relative importance of signaling events during metastasis.
Relevant to this study, members of the classical PKC family (to which PKCa belongs) have been shown to phosphorylate IkBa, induce its degradation and activate nuclear factor kappa B (NF-kB) in Jurkat cells (Steffan et al., 1995) and, specifically, PKCa was found to regulate NF-kB activity in monocytes and normal human epithelial cells (Kawakami et al., 2007; Shin et al., 2007) . Therefore, we determined whether PKCa regulates NF-kB activity in 4T1 mammary cancer cells. As the levels of phosphorylated IkBa are inversely correlated with NF-kB levels and activity (Gross and Piwnica-Worms, 2005) , we measured phosphorylated IkBa levels in tumors from mice after 4 weeks of treatment with aV5-3 or with TAT control. aV5-3 increased the levels of phosphorylated IkBa (normalized with IkBa) by B60% (Figure 5c ). These data suggest that PKCa regulates NF-kB activity in 4T1 mammary cancer in vivo.
We then compared the anti-metastatic efficacy of aV5-3 with both a NF-kB inhibitor (pyrrolidine dithiocarbamate (PDTC)) and an anti-CXCR4 neutralizing antibody. Currently, NF-kB inhibitors and anti-CXCR4 antibodies are in preclinical and clinical development as anti-metastatic therapies for melanoma, renal cell, thyroid and pancreatic cancers, and for lymphomas (Alsayed et al., 2007; Molckovsky and Siu, 2008) . aV5-3 treatment was more effective than the anti-CXCR4 neutralizing antibody and showed equivalent anti-metastatic effects to the NF-kB inhibitor, PDTC, when used in 4T1 tumor-bearing mice (Figure 5d ). Taken together, these data suggest that PKCa regulates NF-kB activity and CXCR4 levels in 4T1-mammary cancer in vivo.
We confirmed the regulation of CXCR4 surface expression by PKCa by measuring cell surface levels of CXCR4 on dissociated primary tumor cells after the above treatments. We found that aV5-3 treatment reduced CXCR4 levels by 60% and NF-kB inhibitor levels by 65%, whereas anti-CXCR4 antibodies reduced CXCR4 levels by only 30% (Figure 5e ). We also found that PKCa regulates NF-kB activity and transcription of CXCR4 (Supplementary Figure 2) in MDA-MB-231 cells in vitro. These data suggest that aV5-3 inhibits cell migration, at least in part, by effectively reducing CXCR4 levels and by inhibiting NF-kB activity. Figure 6 summarizes the stages of metastasis that are regulated by PKCa.
Discussion
Using a syngeneic orthotopic model of breast cancer metastasis in mice, we have shown that pharmacological inhibition of PKCa using a specific inhibitor, aV5-3, almost abrogates metastasis to the lungs. This was evident both in a spontaneous metastasis model (in mice bearing implanted primary tumors) and in a model in which seeding of the lung was measured after intravenous injection of 4T1 breast cancer cells. Figure 6 represents a summary of how PKCa regulates intravasation of cancer cells by increasing the MMP-9 activity and migration of mammary tumor cells by increasing the CXCR4 cell surface levels. We have also shown that PKCa regulates seeding of cancer cells to the lungs. aV5-3 effectively inhibited activity of MMP-9 and NFkB, inhibited tumor cell migration, and seeding and survival of these cancer cells in the secondary organs.
The aV5-3 peptide used in our study was derived from a unique short sequence within the V5 region of PKCa (Mochly-Rosen and Gordon, 1998; Stebbins and Mochly-Rosen, 2001 ). In PKCbII, another member of the classical PKC isozymes, interaction of the C2 and V5 domains of PKC with the receptor for active C kinase, RACK, is needed for PKC activation (Ron et al., 1995; Stebbins and Mochly-Rosen, 2001 ) and peptides derived from either the C2-or the V5-domains have been proven to be effective inhibitors of PKCbII functions (Ron et al., 1995; Stebbins and MochlyRosen, 2001; Kim et al., 2008) . Therefore, we rationally designed a PKCa-inhibitor peptide, reasoning that a Figure 5 aV5-3 reduces cell migration, reduces cell surface levels of CXCR4 and produces a greater reduction in metastasis than anti-CXCR4 antibody in vivo. (a) 4T1 cells (2.5 Â 10 4 in 0.5 ml of media) were serum-starved and were pre-treated for 1 day every 3 h for 9 h with TAT, or aV5-3 at 1 mm. On the day of the experiment, the inserts were placed in wells with serum-containing (10% FBS) media. The same number of control inserts was placed in empty wells of the BD companion plates. Cells were added on top of the wells and incubated with TAT or aV5-3 at 1 mm for 24 h. After incubation, cells migrated (to control inserts) and invaded (to Matrigel inserts) were counted and the percentage of cells invaded/migrated was calculated for each group. (b) Primary tumor lysates from animals treated as in Figure 2 were isolated, dissociated, stained with anti-CXCR4-FITC antibody and analyzed by flow cytometry to measure the cell surface levels of CXCR4 (n ¼ 4 each). (c) Tumors from mice treated with TAT or aV5-3 for 4 weeks were analyzed for phosphoIkBa and non-phosphorylated IkBa levels (n ¼ 4 each). The ratio of phospho-IkBa to IkBa is shown. GAPDH was used as a loading control. (d) Comparison of the anti-metastatic effects of aV5-3 with PDTC (NF-kB inhibitor) or anti-CXCR4 antibody. Peptides were dissolved in saline and administered at a constant rate (0.5 ml/h) corresponding to 24 mg/kg/day (30 mm TAT) and 36 mg/kg/day (30 mm aV5-3-TAT conjugate or aV5-3, in short). PDTC (Sigma, P-8765, 50 mg/kg/day) or anti-CXCR4 antibody (10 mg/ml) was also delivered in osmotic pumps. BLI was used to measure the extent of upper abdominal metastasis after 14 days (n ¼ 5-7 each, *Po0.05 vs TAT). (e) Primary tumor lysates from animals treated as in (d) were isolated, dissociated, stained with anti-CXCR4-FITC antibody and analyzed by flow cytometry to measure the cell surface levels of CXCR4 (n ¼ 5-7 each). A full colour version of this figure is available at the Oncogene journal online.
PKCa antagonist peptide inhibits mammary tumor metastasis J Kim et al peptide derived from the position in V5 that is homologous to the PKCbII-specific inhibitor, bIIV5-3, would be a specific isozyme-selective inhibitor of translocation and function of PKCa.
CXCR4, a seven-transmembrane G protein-coupled receptor, is known to be critical in directional migration and survival of breast cancer cells during the metastatic process, as demonstrated in studies using both human and mouse breast cancer cells (Helbig et al., 2003; Smith et al., 2004; Harvey et al., 2007; Mimeault and Batra, 2007) . Here we found that PKCa is an upstream regulator of CXCR4 levels in the regulation of cell seeding and survival in 4T1 mammary cancer cells. The reduction in the levels of CXCR4 following aV5-3 treatment may partly explain the decreased migration of the cancer cells and the reduced metastasis observed in our study (Figures 2 and 4) .
It is possible that the PKCa inhibitor aV5-3 inhibits interaction of the regulatory domain of PKCa with CXCR4 and, therefore, blocks the recycling of CXCR4 between the cell surface and the intracellular compartment (Peter et al., 2005) . In that case, CXCR4 will mainly remain in the intracellular compartment and the cell surface level will be reduced. However, here we also showed that aV5-3 reduces mRNA levels of CXCR4, suggesting that the actions of aV5-3 could not be solely due to direct interaction between CXCR4 and PKCa.
In terms of therapeutic potential, we found that treatment with aV5-3 significantly increased the survival of tumor-bearing mice, which was associated with a better inhibition of metastasis as compared with treatment with CXCR4 antibodies. Importantly, no signs of toxicity were observed with the aV5-3 treatment in vitro and in vivo. Therefore, aV5-3 represents a promising agent for the prevention and treatment of mammary tumor metastasis. Treatment with selective PKCa inhibitors, such as aV5-3, before or immediately after the surgical removal of the primary tumor may reduce the rates of relapse, by inhibiting tumor metastasis formation.
In conclusion, inhibition of PKCa by aV5-3 increased the survival rate and inhibited intravasation, cell migration and lung seeding, which led to metastasis in a syngeneic orthotopic mouse model of breast cancer. With the efficacy of chemotherapy against advanced or metastatic tumors being generally low and toxic, these findings suggest that a PKCa inhibitor, such as aV5-3, may augment the current therapies of this disease in humans.
Materials and methods

Cell lines
4T1, mouse tumor endothelial cells (2H-11) and MDA-MB-231 cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA); JC cells were provided by the Cancer Research UK cell bank. The 4T1, JC and MDA-MB-231 cells were labeled to stably express firefly luciferase using retroviral infection, as described (Yee et al., 1987) .
Antibodies
For western blot analyses, rabbit antibodies directed against PKC isozymes and Gai-3 (C-10) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), anti-glyceraldehyde 3-phosphate dehydrogenase antibody, and clone 6C5 from Advanced Immunochemical (Long Beach, CA, USA), antibodies for phospho-IkBa and IkBa from Cell Signaling (Danvers, MA, USA), anti-CXCR4 antibody from BioLegend (San Diego, CA, USA) and polyclonal anti-rat CXCR4 neutralizing antibody for the efficacy study from Torrey Pines Biolabs (East Orange, NJ, USA).
Peptide synthesis and drug administration
The PKCa-selective translocation inhibitor (aV5-3) was derived from the PKCa V5 region (QLVIAN) from amino acids 642-647 of PKCa, a position in the V5 domain that is homologous to the positions of bI and bII peptides (Stebbins and Mochly-Rosen, 2001 ). Peptides were synthesized and, for intracellular delivery, were conjugated to a membrane-permeable TAT protein-derived carrier peptide (residues 47-57, YGRKKRRQRRR) as previously described (Chen et al., 2001; Begley et al., 2004) . TAT carrier peptide or saline was used as negative control. Peptides were delivered in vivo using Alzet osmotic mini-pumps (Alzet model 2001, DURECT Corporation, Cupertino, CA, USA), as described (Inagaki , 2005) . The peptides were dissolved in saline and administered at a constant rate (0.5 ml/h) corresponding to 24 mg/kg/day (30 mm TAT) and 36 mg/kg/day (30 mm aV5-3-TAT conjugate or aV5-3, in short). In some experiments, pyrrolidine dithiocarbamate (Sigma, St Louis, MO, USA; P-8765, 50 mg/kg/day) or anti-CXCR4 antibody (10 mg/ml) was also delivered in these Alzet osmotic pumps. Pumps were replaced every 2 weeks, which corresponds to the stability of the peptides in the pump (Inagaki et al., 2005) . MMP-2/9 inhibitor (SB-3CT pMS, Calbiochem, San Diego, CA, USA; #444285) was used at 10 mm in vitro.
Animal tumor models All animal experimentation was conducted according to the protocols approved by the Stanford University Institutional Animal Care and Use Committee. Female BALB/c mice, 6 weeks old, were purchased from Charles River Laboratories (Wilmington, MA, USA), housed at the animal care facility at Stanford University Medical Center (Stanford, CA, USA) and kept under standard temperature, humidity and timed lighting conditions, and provided mouse chow and water ad libitum. 4T1-luc, JC-luc or MDA-MB-231-luc tumor cells were injected directly into the mammary fat pad of the mice in 0.1 ml of sterile Dulbecco's modified Eagle's medium (100 000 or 2 500 000 cells/animal). Peptide treatment began when the tumors reached an average size of 100 mm 3 , which occurred after about 1 week, unless otherwise stated. For the lung seeding study, 100 000 4T1-luc cells in sterile PBS were injected via the tail vein. Animals were treated with PBS, peptide inhibitors, pyrrolidine dithiocarbamate or anti-CXCR4 antibody delivered in osmotic pumps as described above.
Bioluminescence imaging
Mice received luciferin (300 mg/kg, 10 min prior to imaging) and were anesthetized and imaged in an IVIS100 imaging system (Xenogen, part of Caliper Life Sciences, Hopkins, MA, USA). Images were analyzed with Living Image software (Xenogen, part of Caliper Life Sciences). Bioluminescent flux (photons/sec/sr 2 /cm 2 ) was determined for the lungs and rib cages (upper abdominal region of interest), or the primary tumors.
Immunoblot analysis
Tumors were processed as previously described (Kim et al., 2008) . Translocation of PKCa, bII and e was measured by determining their levels in cytosolic and particulate fractions from tumor samples, as described (Begley et al., 2004; Inagaki et al., 2005) .
RNA interference siRNA duplexes targeting PKCa were obtained from Santa Cruz Biotechnology (mouse, sc-36244) . This siRNA product consists of pools of three target-specific 19-25 nucleotide siRNAs for reducing PKCa gene expression (see sequences in the Supplementary materials). Cells at B95% confluency were transfected with control siRNA and PKCa siRNA using transfection reagents from Gene Silencer (San Diego, CA, USA) and lipofectamine from Invitrogen (Carlsbad, CA, USA) according to the manufacturer's instructions. The cells and medium were collected 48 h after transfection.
In vitro intravasation assay Primary human endothelial cells (human umbilical vein endothelial cells from Lonza, Allendale, NJ, USA) or mouse tumor endothelial cells (2H-11 from ATCC) were grown on top of a Matrigel plug in tissue culture inserts in 24-well plates. Intravasation assays were carried out as previously described (Kim et al., 2000) .
In vitro invasion assay The assay was carried out according to the manufacturer's instructions (Becton Dickinson 354483) . The same number of control inserts without Matrigel coating (Becton Dickinson 354578) was used for assessing migration of the cells.
Immunohistochemistry
Freshly obtained lungs were fixed in 4% paraformaldehyde and transferred to 70% ethanol after 24 h. Lungs were then embedded in paraffin, cut into 5 mm sections and mounted on glass slides. Tissue sections on the slides were deparaffinized with xylene, hydrated using a diluted alcohol series, immersed in 3% H 2 O 2 in distilled water for 15 min to quench endogenous peroxidase activity and stained with hematoxylin.
Flow cytometry
Cells were obtained from tissue culture plates or from mechanical dissociation of tumors (through cell filters). Following antibody staining, cells were analyzed on a FACScaliber (BD Pharmingen, San Diego, CA, USA).
Statistical analysis
Data were expressed as mean±s.e.m. Unpaired t-tests for differences between two groups were used to assess significance using Prism 4 software from GraphPad Software (La Jolla, CA, USA; Po0.05).
